TW201325592A - 用於治療癌症之磷脂醯肌醇-3激酶抑制劑 - Google Patents

用於治療癌症之磷脂醯肌醇-3激酶抑制劑 Download PDF

Info

Publication number
TW201325592A
TW201325592A TW101133789A TW101133789A TW201325592A TW 201325592 A TW201325592 A TW 201325592A TW 101133789 A TW101133789 A TW 101133789A TW 101133789 A TW101133789 A TW 101133789A TW 201325592 A TW201325592 A TW 201325592A
Authority
TW
Taiwan
Prior art keywords
nhc
group
phenyl
compound
amino
Prior art date
Application number
TW101133789A
Other languages
English (en)
Chinese (zh)
Inventor
Arthur Decillis
Joanne Lager
Gary Thomas Emmons
Soto Rodrigo Ruiz
Original Assignee
Exelixis Inc
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Sanofi Sa filed Critical Exelixis Inc
Publication of TW201325592A publication Critical patent/TW201325592A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW101133789A 2011-09-14 2012-09-14 用於治療癌症之磷脂醯肌醇-3激酶抑制劑 TW201325592A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US201161562670P 2011-11-22 2011-11-22

Publications (1)

Publication Number Publication Date
TW201325592A true TW201325592A (zh) 2013-07-01

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101133789A TW201325592A (zh) 2011-09-14 2012-09-14 用於治療癌症之磷脂醯肌醇-3激酶抑制劑

Country Status (10)

Country Link
EP (1) EP2755654A1 (cg-RX-API-DMAC7.html)
KR (1) KR20140077911A (cg-RX-API-DMAC7.html)
AU (1) AU2012308414A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014005858A2 (cg-RX-API-DMAC7.html)
CA (1) CA2848724A1 (cg-RX-API-DMAC7.html)
IL (1) IL231448A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02671A (cg-RX-API-DMAC7.html)
TW (1) TW201325592A (cg-RX-API-DMAC7.html)
UY (1) UY34339A (cg-RX-API-DMAC7.html)
WO (1) WO2013040337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
HRP20130902T1 (hr) 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
HRP20140975T1 (hr) * 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
UA98141C2 (ru) * 2007-04-11 2012-04-25 Экселиксис, Инк. Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
WO2013040337A9 (en) 2014-04-03
EP2755654A1 (en) 2014-07-23
WO2013040337A1 (en) 2013-03-21
CA2848724A1 (en) 2013-03-21
IN2014CN02671A (cg-RX-API-DMAC7.html) 2015-07-03
AU2012308414A1 (en) 2014-05-01
IL231448A0 (en) 2014-04-30
BR112014005858A2 (pt) 2017-06-13
KR20140077911A (ko) 2014-06-24
UY34339A (es) 2013-04-30

Similar Documents

Publication Publication Date Title
TWI768087B (zh) 包含帕博西尼(palbociclib)及6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯并[7]輪烯-2-甲酸的組合
TW202521120A (zh) 藥物組合物及其應用
CN104519887B (zh) 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
JP2021098740A (ja) 悪性病変を処置する方法
JP2020147571A (ja) 治療活性を有する化合物及びその使用方法
JP2021130682A (ja) 悪性腫瘍の治療のための併用療法
TW201306842A (zh) 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
TW201601727A (zh) 治療固態腫瘤之方法
CN103202842A (zh) 通过用喹喔啉PI3Kα抑制剂抑制来治疗的方法
TW202216149A (zh) 用於治療非小細胞肺癌之egfr tki
CN121175049A (zh) 治疗包含非典型egfr突变的癌症的egfr抑制剂
WO2024093681A1 (zh) 英菲格拉替尼在治疗胃癌和腺癌中的用途
CN105050602B (zh) 作为pi3激酶抑制剂的吡啶化合物
CN115141188A (zh) 一种取代喹唑啉类化合物、药物组合物及其用途
US20140296265A1 (en) Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR
JP2024067010A (ja) 疾患の治療用のホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤
KR20140077911A (ko) 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제
JP7093764B2 (ja) 骨髄異形成症候群の治療方法
HK40105125A (en) Combinations of fgfr4 inhibitors and bile acid sequestrants
WO2026076001A1 (en) Compositions and methods for use in the treatment of cancer and other indications
HK40131055A (en) A pharmaceutical combination and use thereof
TW202500147A (zh) 雌激素受體降解劑與cdk7抑制劑之組合
WO2025122470A1 (en) Combination therapies for treatment of breast cancer
WO2024130344A1 (en) Transient receptor potential vanilloid 6 inhibitors
WO2013067306A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers